This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate contain the active ingredient Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate. It is indicated to treat Human Immunodeficiency Virus (HIV-1) and Hepatitis B virus infections in adults. Antiviral medications delay the complications related to AIDS and improve the overall quality of life. It is prescribed to stop the reproduction of HIV for as long as possible. Lamivudine got FDA (U.S. Food and Drug Safety Administration.) approved for HIV treatment in November 1995. Nevirapine got FDA approved for HIV treatment in June 1996. Tenofovir disoproxil fumarate got FDA approved for HIV treatment in October 2001.

Mechanism of Action of undefined

Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate work by suppressing viral replication, delaying disease progression, restoring immune function, reducing HIV transmission risk, and improving overall survival and quality of life. It targets different steps in the HIV life cycle, inhibiting viral enzymes, interfering with viral DNA synthesis, and reducing the viral load in the body.

Uses of undefined

Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate are used for HIV-1 Infection and Hepatitis B Infection

undefined Drug administaration and Dosage available

To consume Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate, follow your healthcare provider'sprovider's instructions regarding dosage, frequency, and duration. Take it with or without food, swallowing the tablets or capsules with water. Adhere to the prescribed dosing schedule; do not alter the dosage without consulting your healthcare provider.

Warnings, Precautions and Side Effects of undefined

Warnings

Using Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate carries several warnings. These include the risk of hepatotoxicity (liver toxicity), hypersensitivity reactions, lactic acidosis, immune reconstitution syndrome (antiviral drug causes worsening of previous infection present in the body), bone loss, and renal impairment associated with tenofovir, potential immune system changes, the risk of developing drug resistance, renal impairment, pancreatitis, changes in body fat distribution, and possible mental health effects.

Precautions

Precautions for these medications include monitoring liver function, particularly in individuals with pre-existing liver disease. Signs of severe hypersensitivity reactions or liver toxicity should be closely watched for. The potential risk of lactic acidosis, especially in those with predisposing factors, should be considered. Regular bone density and renal function monitoring is advised for individuals taking Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate.

Side Effects

Side effects of the medications Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate may include but are not limited to nausea, vomiting, diarrhea, headache, fatigue, dizziness, rash, liver toxicity, changes in kidney function, bone loss, increased risk of fractures, changes in cholesterol or blood sugar levels, and potential drug interactions.

Word Of Advice

If you are considering getting Lamivudine, Nevirapine, and Tenofovir disoproxil fumarate, you should know the potential risks and warnings associated with the vaccine. Pregnant and breastfeeding women should always consult a doctor before taking it. Use it cautiously if you have any pre-existing conditions, including previous liver, kidney, pancreas, or bone disease, as it may exacerbate them. Regular blood examination along with monitoring of blood sugar is recommended during treatment. 

Close monitoring and appropriate management are necessary in these cases. Check with your physician if you have a heart condition or electrolyte imbalance. Inform your physician before beginning treatment if you have or ever had a mental illness, fits, Hepatitis infection, skin rashes, or any other signs of infection or inflammation. Adherence to these precautions and regular monitoring and communication with the healthcare provider can help ensure safe and effective use.

Frequently Asked Question

References

  1. Accord Healthcare Limited, Electronic Medicines Compendium (EMC), [Revised on Mar 2021] [Accessed on 20th May 2023], https://www.medicines.org.uk/emc/files/pil.8888.pdf
  2. Cipla (EU) Limited, Electronic Medicines Compendium (EMC), [Revised on Oct 2017] [Accessed on 20th May 2023], https://www.medicines.org.uk/emc/files/pil.10500.pdf
  3. KD Tripathi, Antiviral Drugs (Anti-retrovirus), Essentials of Medical Pharmacology, 8th Edition, 2019, 860-872
  4. Sharon Safrin, Antiviral Agents, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 863-894

Disclaimer

The drug information on this page is different from medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.